<code id='6E94A77CFE'></code><style id='6E94A77CFE'></style>
    • <acronym id='6E94A77CFE'></acronym>
      <center id='6E94A77CFE'><center id='6E94A77CFE'><tfoot id='6E94A77CFE'></tfoot></center><abbr id='6E94A77CFE'><dir id='6E94A77CFE'><tfoot id='6E94A77CFE'></tfoot><noframes id='6E94A77CFE'>

    • <optgroup id='6E94A77CFE'><strike id='6E94A77CFE'><sup id='6E94A77CFE'></sup></strike><code id='6E94A77CFE'></code></optgroup>
        1. <b id='6E94A77CFE'><label id='6E94A77CFE'><select id='6E94A77CFE'><dt id='6E94A77CFE'><span id='6E94A77CFE'></span></dt></select></label></b><u id='6E94A77CFE'></u>
          <i id='6E94A77CFE'><strike id='6E94A77CFE'><tt id='6E94A77CFE'><pre id='6E94A77CFE'></pre></tt></strike></i>

          Home / hotspot / entertainment

          entertainment


          entertainment

          author:fashion    Page View:7
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In